Quantcast

Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit – A Comprehensive Approach to the Management of Atopic Dermatitis

March 9, 2010

RALEIGH, N.C., March 9 /PRNewswire/ — Arbor Pharmaceuticals (“Arbor”), a specialty pharmaceutical company focused exclusively on pediatric medicine, announced today that the company has launched Pediaderm(TM) HC Complete Kit – an innovative new product for the comprehensive management of atopic dermatitis. Pediaderm HC Complete Kit contains Pediaderm HC (Hydrocortisone Lotion USP 2%) and patented Pediaderm Protective Emollient with Triple Synergy Technology(TM). Pediaderm HC Complete Kit has been specifically developed to treat, manage, and protect the skin of children with atopic dermatitis, commonly referred to as eczema.

Atopic Dermatitis (AD) is the most common chronic inflammatory skin condition among US children, and the prevalence is increasing worldwide(1). The American Academy of Dermatology recommends the use of topical corticosteroids to treat the acute flares of AD and the concomitant use of emollients to hydrate, protect and restore the skin(2). Importantly, the presence of certain skin pathogens – most notably Staphylococcus aureus (S. aureus) – have been shown to contribute to the worsening and persistence of AD, while also contributing to problematic skin infections(3).

“Arbor is excited to introduce this novel and comprehensive approach to the treatment and management of atopic dermatitis for children suffering from this troubling disease. The patented Triple Synergy Technology contained within the Pediaderm Protective Emollient is a unique technology that provides an innovative approach to treating AD. As a pediatric pharmaceutical company our mission is to introduce novel products that offer better solutions for the most common childhood illnesses. Pediaderm HC Complete Kit represents another important step for the company in fulfilling that mission,” stated Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals.

Pediaderm HC Complete Kit is the first and only product that provides a comprehensive approach to treating and managing atopic dermatitis. Pediaderm HC contains the lowest prescription-only dose of hydrocortisone in a child-friendly, fast-drying form and is safe to use on all ages and all areas of the body(4). The patented Pediaderm Protective Emollient is a uniquely formulated cream specifically designed to rehydrate, replenish and restore the integrity of skin damaged by atopic dermatitis. Importantly, Pediaderm Protective Emollient incorporates the patented Triple Synergy Technology(TM) which has been proven to eradicate a wide range of bacteria, fungi and viruses, including Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (MRSA), two common causes of skin infections which are often difficult to treat(5).

Pediaderm HC Complete Kit is available by prescription only at retail pharmacies across the U.S. Pediaderm HC Complete Kit is directly promoted to U.S. pediatricians by Arbor Pharmaceuticals’ specialty sales force. Pediaderm HC Complete Kit is Arbor Pharmaceuticals’ fourth product launch since the company initiated commercial operations less than two years ago.

Important Safety Information

Pediaderm HC Complete Kit is available by prescription only.

Pediaderm HC Lotion

Pediaderm HC Lotion is for topical use only and should not be used ophthalmically.

Pediaderm HC Lotion is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Pediaderm HC is contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. Prolonged use may produce reversible HPA axis suppression. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if a concomitant skin infection develops. Patients may experience local adverse reactions, including burning, itching, irritation, and dryness. Discontinue use and contact your healthcare professional if irritation persists.

Pediaderm Protective Emollient

Pediaderm Protective Emollient is nonsteroidal and is intended for topical use only.

Pediaderm Protective Emollient is contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. Discontinue use and contact your healthcare professional if irritation develops.

About Arbor Pharmaceuticals

Arbor Pharmaceuticals, headquartered in Raleigh, North Carolina, is a specialty pharmaceutical company focused exclusively on the growing pediatric market. The company intends to become the leading pediatrics-focused pharmaceutical company by actively licensing, developing and commercializing late-stage products for significant pediatric conditions. In addition to PEDIADERM(TM) HC COMPLETE KIT, Arbor also currently markets three nonantibiotic products for varying otic conditions including XYLAREX®, ZINOTIC® and NEOTIC®.

For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com or send email inquiries to info@arborpharma.com.

See www.pediaderm.com for full prescribing information.

(1) Horii KA, Simon SD, Liu DY, Sharma V. Atopic Dermatitis in Children in the United States, 1997 2004: Visit Trends, Patient and Provider Characteristic, and Prescribing Patterns. Pediatrics 2007; 120;e527-e534
(2) Hanifin J et al. Guidelines of care for Atopic Dermatitis. J Am Acad Dermatol; 2004; 50:391-404.

(3) Huang J, Abrams M, Tlougan B, Rademaker A, Paller A. Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity. Pediatric; 2009; 123; e808-e814.

(4) Wolters Kluwer Health. Medispan-PriceRx 12/2009.

(5) Data on File. Arbor Pharmaceuticals, Inc.

Xylarex, Zinotic, and Neotic are registered trademarks of Arbor Pharmaceuticals, Inc.

SOURCE Arbor Pharmaceuticals


Source: newswire



comments powered by Disqus